| Literature DB >> 26765287 |
Weiping Cao1, Justine S Liepkalns1, Ahmed O Hassan2, Ram P Kamal3, Amelia R Hofstetter4, Samuel Amoah3, Jin Hyang Kim1, Adrian J Reber1, James Stevens5, Jacqueline M Katz1, Shivaprakash Gangappa1, Ian A York1, Suresh K Mittal6, Suryaprakash Sambhara7.
Abstract
Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine. Published by Elsevier Ltd.Entities:
Keywords: A/H7N9 influenza vaccine; Adenoviral vector vaccine; Antibody responses; H7HA, cell-mediated immunity; Mouse model; Protective immunity
Mesh：
Substances：
Year: 2016 PMID： 26765287 PMCID： PMC4735641 DOI： 10.1016/j.vaccine.2015.12.062
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641